Home/Products /lapatinib-250-mg-tablet

LAPANIB 250 Tablet: Lapatinib 250 mg - Targeted Oncology Therapy for HER2+ Cancer

Name: LAPANIB 250: Lapatinib 250 mg Tablet
Brand: Lapanib 250 Tablet
Rating: 4.8 (150 reviews)

Dual Tyrosine Kinase Inhibition: The Mechanism of Lapatinib

Primary Indication: In Combination with Capecitabine for Advanced HER2+ Cancer

Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer Regimen

The Therapeutic Advantage: Crossing the Cell Barrier to Block HER2 and EGFR

Secure Your Monopoly: LAPANIB 250 PCD Pharma Franchise with Specialized Support

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Lapatinib 250 mg tablet strip for metastatic breast cancer.

Oral targeted therapy tablet for HER2-positive cancer.

Oncology PCD Pharma franchise marketing visual for Lapatinib.

Lapanib 250 Tablet

Composition : Lapatinib (250 mg) Tablet

Dosage Form : Tablet

Packaging Type : in a Bottle

Packaging : 30 Tablets

Price : ₹1/-

Please Contact For Best Price

LAPANIB 250 Tablet (Lapatinib 250 mg) is a highly specialized, oral, targeted cancer medicine classified as a Dual Tyrosine Kinase Inhibitor (TKI). It is a critical treatment component for patients diagnosed with HER2-positive advanced or metastatic breast cancer.

Mechanism and Impact:Lapatinib works by selectively and reversibly binding to the intracellular domain of two key receptors: Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR). By competitively blocking the signaling pathways, Lapatinib effectively halts the uncontrolled tumor cell growth. This dual-action mechanism is particularly valuable in treating cancers that have progressed following treatment with other HER2-targeted agents.

Key Therapeutic Uses (Combination Therapy):

With Capecitabine: For patients whose cancer has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab.
With Letrozole: For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.

We offer an exclusive PCD Pharma Franchise opportunity for LAPANIB 250, providing partners with monopoly rights in this specialized, high-demand segment of targeted breast cancer therapeutics.

About the Product

Key Therapeutic Uses (Combination Therapy):

With Capecitabine: For patients whose cancer has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab.
With Letrozole: For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.

Common side effects include nausea, dizziness, stomach discomfort, muscle pain, headache, and an increased risk of bleeding or bruising.

Rosutyle Gold 20/150 Tablet is prescribed for individuals at high risk of cardiovascular diseases, including heart attack, stroke, and atherosclerosis, especially those with high cholesterol and hypertension.

Use only under medical supervision. Regular monitoring of cholesterol levels, liver function, and bleeding risk is recommended.

Store at room temperature (15-30°C) in a dry place away from direct sunlight and moisture. Keep out of reach of children.